Key facts
- Cellyrix Therapeutics’s last known valuation is $3.0M (Sep 2025).
- It has raised $1.4M; the latest was Seed Round ($1.4M) in Sep 2025.
- Notable investors include AION Labs, Amiti Ventures, AstraZeneca, Israel Biotech Fund, Teva Pharmaceutical Industries — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Cellyrix Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellyrix Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellyrix Therapeutics
Operator of a biotechnology company intended to introduce a new modality into cancer treatment. The company helps in treatment challenges such as therapy resistance, metastasis, and relapse, enabling cancer patients to get quality treatment via single-cell sequencing and artificial intelligence.
- Sector
- Healthcare
- HQ
- Rehovot, Israel
- Founded
- 2024
- Employees
- 7
- Ownership
- Privately Held (backing)
Cellyrix Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellyrix Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellyrix Therapeutics in its N-PORT filings yet. We sweep new filings monthly.